Skip to main content

5α-Reductase Inhibitors (5-ARIs)

Category: Pharmacology > Voiding & Outlet Last reviewed: April 2026

Overview​

5α-reductase inhibitors (5-ARIs) block the conversion of testosterone to dihydrotestosterone (DHT) — the primary androgen driving prostate growth. Two agents are FDA-approved: finasteride (type 2 5α-reductase selective) and dutasteride (dual type 1 + type 2 inhibitor). 5-ARIs shrink the prostate ~20–25%, improve IPSS by 3–4 points, and — unlike α-blockers — reduce the risk of acute urinary retention and need for BPH surgery in men with enlarged prostates.[1][2]

Onset of clinical benefit takes 3–6 months. 5-ARIs are therefore the static-obstruction complement to α-blockers' dynamic-obstruction effect, and the combination has been established as superior to either alone in men at risk of BPH progression (MTOPS).

5-ARIs sit at the center of three contemporary controversies worth understanding:

  1. The PCPT/REDUCE high-grade cancer signal, now largely explained as detection bias
  2. The depression / suicide / cognitive signal (post-finasteride syndrome), with mixed evidence but FDA-mandated labeling
  3. The need to double observed PSA in men on 5-ARIs to avoid delayed cancer diagnosis

Mechanism of Action​

5α-reductase isoenzymes catalyze the conversion of testosterone → DHT. DHT binds the androgen receptor with higher affinity than testosterone and drives prostate growth.

IsoenzymeTissue distributionBlocked by
Type 1Skin, scalp, liverDutasteride only
Type 2Prostate, seminal vesicles, genital skin, liverBoth finasteride and dutasteride

Consequences of isoenzyme selectivity​

ParameterFinasteride (type 2 only)Dutasteride (dual)
Serum DHT reduction70–90%~95% (near-zero)
Prostate volume reduction18–25%20–27%
IPSS improvement3–4 points3–4 points
Clinical BPH outcomesComparableComparable (EPICS trial)
Scalp / skin effectYes (also used for androgenetic alopecia at 1 mg)Yes (off-label for alopecia)

Despite the deeper DHT suppression with dutasteride, head-to-head data (EPICS trial) show comparable BPH clinical outcomes between the two agents. Agent selection often comes down to cost, formulary, and specific sexual-side-effect concerns.

Agents in This Class​

Generic NameBrand Name(s)Isoenzyme TargetRouteDoseNotes
FinasterideProscar (BPH), Propecia (alopecia, 1 mg)Type 2 onlyPO5 mg daily for BPHLonger clinical track record; generic
DutasterideAvodart; Jalyn (combo w/ tamsulosin)Dual type 1 + 2PO0.5 mg dailyDeeper DHT suppression; longer half-life (~5 weeks); combination product available

Indications in Reconstructive Urology​

BPH / LUTS with enlarged prostate (FDA-approved)​

The core indication. 5-ARIs are most effective in prostates ≥30 mL (or PSA >1.5 ng/mL as a surrogate for volume).[1][2]

Clinical benefits over placebo:

  • IPSS improvement: 3–4 points
  • Prostate volume reduction: 18–27%
  • PSA reduction: ~50% at 6–12 months
  • Acute urinary retention (AUR) reduction: ~50% relative risk reduction
  • Need for BPH surgery reduction: ~50% relative risk reduction
  • Onset: 3–6 months to meaningful clinical effect; 12 months for full benefit

Combination therapy with α-blockers — MTOPS​

See α-blockers for the MTOPS data. Key points:

RegimenClinical progression vs placebo
Placebo—
Doxazosin alone39% ↓
Finasteride alone34% ↓
Combination66% ↓

Only combination therapy and finasteride (but not doxazosin alone) reduced the risk of acute urinary retention and invasive BPH therapy.[1]

Candidates for combination therapy:

  • Prostate volume ≥30–40 mL
  • Elevated PSA (indicating progression risk)
  • Moderate-to-severe LUTS on α-blocker monotherapy
  • Prior episode of AUR
  • Young patients who will likely benefit from long-term prostate-volume control

Gross hematuria from enlarged vascular prostate​

Finasteride reduces bleeding from prostatic vessels — useful adjunct in recurrent gross hematuria due to prostatic enlargement. Onset 3–6 months; not a first-line acute therapy.

Androgenetic alopecia (finasteride 1 mg — Propecia)​

A separate indication at lower dose. Outside primary urologic scope but relevant because the post-finasteride-syndrome controversy emerged largely from this population (younger men, elective use for cosmetic indication).

Chronic prostatitis — not indicated​

5-ARIs are not recommended for CP/CPPS. The AUA prostatitis guideline positions α-blockers as first-line oral therapy; 5-ARIs are not part of the stepped framework.[4]

Dosing & Administration​

warning

Doses listed are for reference only. Confirm with current guidelines and institutional protocols.

AgentDoseAdministration
Finasteride (BPH)5 mg PO dailyWith or without food
Finasteride (alopecia)1 mg PO daily—
Dutasteride0.5 mg PO dailyWith or without food
Dutasteride + tamsulosin (Jalyn)0.5 mg / 0.4 mg PO daily30 min after same meal daily

Onset of effect​

  • Symptomatic improvement: 3–6 months
  • Maximum prostate volume reduction: ~12 months
  • PSA stabilization: 6–12 months

Duration​

5-ARIs are typically lifelong therapy for BPH. Discontinuation leads to prostate regrowth and symptom recurrence within months.

Pregnancy and handling​

  • Both agents are contraindicated in pregnancy (category X — teratogenic risk to male fetus, hypospadias)
  • Women of childbearing potential should not handle crushed/broken tablets or open capsules — the drugs absorb through skin
  • Male patients should use condoms if their partner is or may become pregnant (semen contains small amounts of drug)

Contraindications & Precautions​

Absolute contraindications​

  • Pregnancy / women of childbearing potential — category X teratogen (male fetal genitourinary malformations)
  • Hypersensitivity to finasteride, dutasteride, or other 4-azasteroids
  • Pediatric use — not indicated

Relative contraindications / cautions​

  • Active depression or prior depressive episodes — document patient awareness of the depression/suicide signal before initiation
  • History of infertility concerns — semen parameter changes possible (small but real)
  • Significant hepatic impairment — both agents metabolized by CYP3A4; use caution
  • Planned prostate cancer screening — double the observed PSA to get the true value (see PSA monitoring section)

Drug interactions​

  • Strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, clarithromycin) — may increase dutasteride levels; monitor
  • No clinically significant interaction with α-blockers (the combination is the point)
  • No meaningful interaction with PDE5 inhibitors

Adverse Effects​

Sexual side effects (1–8%)[1][2][7]​

AERateNotes
Decreased libido3–7%Usually onset in first months
Erectile dysfunction5–8%Often responsive to PDE5i
Ejaculatory dysfunction (decreased volume)1–3%Distinct from α-blocker-induced anejaculation
Gynecomastia1–2%DHT/estrogen balance shift
Breast tendernessLowReport to patient

Sexual adverse events tend to decrease after the first year of therapy and are typically reversible on discontinuation in most men.[5][7]

Post-finasteride syndrome (PFS) — the controversy​

A constellation of persistent sexual, neuropsychiatric, and cognitive symptoms reported to persist after discontinuation in some men. The medical community's position has evolved:

  • FDA received post-marketing reports of self-harm and suicide associated with finasteride → depression and suicidal ideation added to both agents' product monographs[3]
  • Welk 2017 JAMA Internal Medicine case-control study found associations between 5-ARI use and depression/self-harm, particularly in the first 18 months
  • Garcia-Argibay 2022 Swedish cohort found associations with dementia and depression during initial treatment years, though suicide risk not significantly elevated[8]
  • Mechanistic plausibility: 5-ARIs reduce neurosteroids (allopregnanolone, tetrahydrodeoxycorticosterone) that modulate GABA-A receptors — a biologically plausible pathway for mood/cognitive effects

Clinical approach:

  • Screen for baseline mood disorders before initiation
  • Counsel explicitly about the depression/suicide signal
  • Low threshold for discontinuation if mood symptoms emerge
  • Document consent conversation

Other adverse effects​

  • Sperm count / motility reduction — small but real; generally insufficient to reduce fertility in men with normal baseline semen[9]
  • Gynecomastia in 1–2%
  • Male breast cancer — rare post-marketing reports; causality unclear

PSA Monitoring on 5-ARIs​

The 50% rule​

5-ARIs reduce PSA by approximately 50% at 6–12 months. When screening for prostate cancer in men on 5-ARIs:[2][6][19]

Multiply the observed PSA by 2 to obtain the "true" PSA value for interpretation.

Clinical implications​

  • Check baseline PSA before initiation
  • Re-baseline at 6–12 months of therapy — this is the new reference
  • Any rise in PSA from the on-treatment baseline is concerning and warrants investigation — do not attribute to "normal variation"
  • Failure to adjust PSA values leads to delayed prostate cancer diagnosis — the Sarkar 2019 JAMA Internal Medicine study showed 5-ARI users had longer time-to-diagnosis and worse mortality when PSA was not correctly interpreted[6]
  • PSA velocity cutoffs may need adjustment in the 5-ARI-exposed population

Practical implementation​

Label the patient's chart so that every clinician interpreting PSA knows they are on a 5-ARI. "PSA 2.0 on 5-ARI → true PSA ~4.0" is the mental math to perform.

Prostate Cancer Prevention — the PCPT/REDUCE Story​

Two landmark chemoprevention trials and their reinterpretation have shaped contemporary 5-ARI positioning:

PCPT (Prostate Cancer Prevention Trial) and REDUCE​

  • Finasteride (PCPT) and dutasteride (REDUCE) each reduced overall prostate cancer incidence by ~23–25%[10][11][12]
  • BUT both trials showed an increased proportion of high-grade tumors (Gleason ≥7) in the 5-ARI groups
  • FDA 2011 safety warning added based on this signal; 5-ARIs are not FDA-approved for cancer prevention

Reinterpretation — detection bias​

The contemporary understanding:[10][13][16]

  • 5-ARIs shrink the prostate, improving biopsy sampling accuracy
  • High-grade cancers are easier to detect in smaller prostates — producing apparent "increased" high-grade incidence that is really a detection bias artifact
  • 18-year PCPT follow-up: no difference in prostate cancer-specific mortality; non-significant 25% reduction in cancer deaths with finasteride[14]
  • Multiple meta-analyses (Baboudjian 2023, Hamilton 2024, Björnebo 2022): no association between 5-ARI use and prostate cancer mortality[10][13][15]

Current nuanced position​

  • 5-ARIs reduce risk of low- and intermediate-grade (Gleason 6–7) prostate cancer[11][17][18]
  • No increase in high-grade cancer when detection bias is accounted for
  • Not FDA-approved for prevention, but the historical risk framing is outdated
  • AUA/ASCO 2008 guideline for chemoprevention use is dated — contemporary practice does not actively use 5-ARIs for cancer prevention, though the risk calculus for BPH use is now more favorable than the 2011 black-box era suggested

Perioperative Considerations​

Before TURP / HoLEP / other BPH surgery​

  • Traditional teaching: stop 5-ARI 2 weeks before prostate surgery to avoid compromising bleeding control
  • Modern evidence is mixed — some series show less intraoperative bleeding with continued 5-ARI (reduced microvessel density), others show no difference
  • Most contemporary protocols continue 5-ARIs perioperatively
  • If discontinued: safe to resume 2–4 weeks postop once hemostasis confirmed

Perioperative PSA monitoring​

  • Do not interpret post-surgical PSA without accounting for both the 5-ARI and the surgical tissue reduction
  • Reset PSA baseline 3–6 months postop after the acute inflammatory component resolves

Combination with minimally invasive BPH therapy​

  • UroLift, Rezūm, iTind: 5-ARIs can be continued or considered post-procedure depending on prostate volume and response
  • Aquablation, HoLEP, simple prostatectomy: typically can discontinue 5-ARI postoperatively if surgical debulking has resolved symptoms

Evidence Summary​

IndicationEvidence LevelKey Trial / GuidelineNotes
BPH/LUTS with enlarged prostateLevel 12023 AUA BPH Guideline amendmentProstate ≥30 mL or PSA >1.5 ng/mL
Combination w/ α-blockerLevel 1MTOPS 2003 (McConnell NEJM)[[25 — see α-blockers]]; CombAT (dutasteride + tamsulosin)66% ↓ progression; superior for AUR prevention
PSA halving (double observed value)Level 1Sarkar 2019 JAMA Intern Med[6]Failure to adjust → delayed cancer diagnosis
Prostate cancer prevention — overall riskLevel 1PCPT, REDUCE[10][11][12]~25% reduction; not FDA-approved for this
High-grade cancer signalLevel 1 (reinterpreted)PCPT 18-yr f/u[14]; Björnebo 2022[13]; meta-analyses[10][11][15]No association with mortality; detection bias
Depression / suicide signalLevel 2–3 (mixed)Welk 2017[3]; Garcia-Argibay 2022[8]; FDA labelingMechanistically plausible; counsel patient
Gross hematuria from BPHLevel 2ObservationalFinasteride reduces prostatic microvessel bleeding

Practical Pearls​

  1. Double the PSA on every 5-ARI patient. Label the chart. Any rise above the on-treatment baseline is cancer until proven otherwise.
  2. 3–6 months for clinical effect — set expectations up front; don't let the patient quit at 2 months for "not working."
  3. Combination therapy is the MTOPS lesson — for the enlarged-prostate, high-PSA, retention-risk patient, don't sequence; combine from the start.
  4. Dutasteride vs finasteride clinically comparable despite deeper DHT suppression (EPICS) — choose on cost, formulary, and patient-specific factors.
  5. Counsel about depression/suicide before initiation. The signal is mixed but the FDA labeling is clear, and the documentation protects both patient and clinician.
  6. The PCPT/REDUCE "high-grade cancer" signal is now understood as detection bias — contemporary meta-analyses show no mortality increase. Still, 5-ARIs are not approved for prevention.
  7. Women of childbearing potential must not handle broken tablets — this is a real teratogenic risk, not a hypothetical one.
  8. Gynecomastia in 1–2% — ask about breast symptoms at follow-up.
  9. Post-finasteride syndrome is controversial but real enough to document — low threshold to discontinue if mood symptoms emerge.
  10. Sexual side effects usually resolve in the first year on continued therapy or on discontinuation — inform the patient that initial sexual AEs may improve.

References​

1. Wei JT, Dauw CA, Brodsky CN. Lower urinary tract symptoms in men. JAMA. 2025;334(9):809–821. doi:10.1001/jama.2025.7045

2. Sarma AV, Wei JT. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367(3):248–57. doi:10.1056/NEJMcp1106637

3. Welk B, McArthur E, Ordon M, et al. Association of suicidality and depression with 5α-reductase inhibitors. JAMA Intern Med. 2017;177(5):683–691. doi:10.1001/jamainternmed.2017.0089

4. Food and Drug Administration. Proscar (finasteride) prescribing information. Updated 2026-03-18.

5. Oesterling JE. Benign prostatic hyperplasia — medical and minimally invasive treatment options. N Engl J Med. 1995;332(2):99–109. doi:10.1056/NEJM199501123320207

6. Sarkar RR, Parsons JK, Bryant AK, et al. Association of treatment with 5α-reductase inhibitors with time to diagnosis and mortality in prostate cancer. JAMA Intern Med. 2019;179(6):812–819. doi:10.1001/jamainternmed.2019.0280

7. Kramer BS, Hagerty KL, Justman S, et al. Use of 5α-reductase inhibitors for prostate cancer chemoprevention: ASCO/AUA 2008 clinical practice guideline. J Urol. 2009;181(4):1642–57. doi:10.1016/j.juro.2009.01.071

8. Garcia-Argibay M, Hiyoshi A, Fall K, Montgomery S. Association of 5α-reductase inhibitors with dementia, depression, and suicide. JAMA Netw Open. 2022;5(12):e2248135. doi:10.1001/jamanetworkopen.2022.48135

9. Drobnis EZ, Nangia AK. 5α-reductase inhibitors (5ARIs) and male reproduction. Adv Exp Med Biol. 2017;1034:59–61. doi:10.1007/978-3-319-69535-8_7

10. Hamilton RJ, Chavarriaga J, Khurram N, et al. 5-α reductase inhibitors and prostate cancer mortality. JAMA Netw Open. 2024;7(8):e2430223. doi:10.1001/jamanetworkopen.2024.30223

11. Luo LM, Yang RD, Wang JM, et al. Association between 5α-reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis. Asian J Androl. 2020;22(5):532–538. doi:10.4103/aja.aja_112_19

12. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24. doi:10.1056/NEJMoa030660

13. Björnebo L, Nordström T, Discacciati A, et al. Association of 5α-reductase inhibitors with prostate cancer mortality. JAMA Oncol. 2022;8(7):1019–1026. doi:10.1001/jamaoncol.2022.1501

14. Goodman PJ, Tangen CM, Darke AK, et al. Long-term effects of finasteride on prostate cancer mortality. N Engl J Med. 2019;380(4):393–394. doi:10.1056/NEJMc1809961

15. Baboudjian M, Gondran-Tellier B, Dariane C, et al. Association between 5α-reductase inhibitors and prostate cancer mortality: a systematic review and meta-analysis. JAMA Oncol. 2023;9(6):847–850. doi:10.1001/jamaoncol.2023.0260

16. Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15(11):e484–92. doi:10.1016/S1470-2045(14)70211-6

17. Wallerstedt A, Strom P, Gronberg H, Nordstrom T, Eklund M. Risk of prostate cancer in men treated with 5α-reductase inhibitors — a large population-based prospective study. J Natl Cancer Inst. 2018;110(11):1216–1221. doi:10.1093/jnci/djy036

18. Preston MA, Wilson KM, Markt SC, et al. 5α-reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014;174(8):1301–7. doi:10.1001/jamainternmed.2014.1600

19. Pattanaik S, Mavuduru RS, Panda A, et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2018;11:CD010060. doi:10.1002/14651858.CD010060.pub2